Literature DB >> 24922641

Heparanase and COX-2 expression as predictors of lymph node metastasis in large, high-grade breast tumors.

Stephanie Gawthorpe1, James E Brown2, Muhammad Arif3, Peter Nightingale4, Alan Nevill5, Amtul R Carmichael6.   

Abstract

BACKGROUND/AIM: Heparanase (HPA) contributes to breast cancer metastasis by facilitating the breakdown of the basement membrane and extracellular matrix. High expression of HPA is thought to be associated with increased nodal involvement and poor survival in patients with breast cancer. Overexpression of cyclooxygenase-2 (COX-2) in breast cancer is associated with indicators of poor prognosis such as lymph node metastasis, poor differentiation, and large tumor size. The underlying mechanism by which HPA and COX-2 overexpression increases the metastatic potential of breast cancer is not fully-understood. To enhance our understanding over these mechanisms, we aimed to investigate the relationship between the size of the tumor and HPA expression, tumor grade as well as lymph node status in patients with breast cancer.
MATERIALS AND METHODS: Immunohistochemical analysis of HPA and COX-2 expression was performed on 246 breast tumor samples. The expression of HPA was correlated with COX-2 expression, tumor grade, lymph node status, oestrogen receptor status.
RESULTS: The overexpression of HPA and COX-2 was associated with increased likelihood of lymph node positivity in large, high-grade tumors. High-grade tumors with size greater than 20 mm, that overexpressed HPA, were 4-times more likely to be associated with lymph node involvement (OR 4.71, CI 1.21-18.25). Whereas, tumors greater than 20 mm in size were 5-times more likely to metastasize to the regional lymph nodes, if associated with overexpression of COX-2 (OR 5.5, CI 1.2-24.8).
CONCLUSION: Expression of HPA appears to be a key mechanism by which large, high-grade breast tumors metastasize to regional lymph nodes, while COX-2 overexpression may be an independent predictor of lymph node positivity. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Breast cancer; heparanase; lymph nodes; tumor grade

Mesh:

Substances:

Year:  2014        PMID: 24922641

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Effect of photodynamic therapy combined with Celecoxib on expression of cyclooxygenase-2 protein in HeLa cells.

Authors:  Yuanfu Mao; Lishuang Wang; Chen Xu; Shiyu Han
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

Review 2.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

Review 3.  New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.

Authors:  Honor J Hugo; C Saunders; R G Ramsay; E W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-21       Impact factor: 2.673

4.  IMP1 suppresses breast tumor growth and metastasis through the regulation of its target mRNAs.

Authors:  Guangli Wang; Zhenqiang Huang; Xin Liu; Wenhe Huang; Shaoying Chen; Yanchun Zhou; Deling Li; Robert H Singer; Wei Gu
Journal:  Oncotarget       Date:  2016-03-29

Review 5.  Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data.

Authors:  Xu Sun; Ganlin Zhang; Jiayun Nian; Mingwei Yu; Shijian Chen; Yi Zhang; Guowang Yang; Lin Yang; Peiyu Cheng; Chen Yan; Yunfei Ma; Hui Meng; Xiaomin Wang; Jin-Ping Li
Journal:  Oncotarget       Date:  2017-06-27

6.  Correlation between heparanase gene polymorphism and susceptibility to endometrial cancer.

Authors:  Hanyu Cao; Shuo Yang; Xiuzhang Yu; Mingrong Xi
Journal:  Mol Genet Genomic Med       Date:  2020-09-01       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.